Payment overview · 2025
General Payments
$504.79
24 reported records · 11 companies
Healthcare provider profile · identity verified
Shiv Kumar Aggarwal, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NEW PORT RICHEY, FL · NPI 1376552075
Verified facts
What the public records show
CMS Open Payments records show Shiv Kumar Aggarwal, M.D. received $504.79 in general payments during 2025 across 24 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $106.12 | 21.0% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $86.88 | 17.2% | 3 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $71.64 | 14.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $62.52 | 12.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.87 | 7.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.82 | 7.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.04 | 4.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.54 | 4.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.69 | 4.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.31 | 3.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $17.36 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $504.79 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $86.88 | 3 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $71.64 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $63.60 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $42.80 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $42.80 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $42.52 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $24.04 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 2 Normalized: freestyle libre 2 |
Device | Abbott Laboratories | $21.54 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $19.95 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.69 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.69 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $17.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 22 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
122 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 858 | 255 |
| Omeprazole | Omeprazole | 443 | 131 |
| Levothyroxine Sodium | Levothyroxine Sodium | 435 | 110 |
| Metformin Hcl | Metformin Hcl | 401 | 115 |
| Alprazolam | Alprazolam | 382 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 313 | 94 |
| Lisinopril | Lisinopril | 284 | 92 |
| Furosemide | Furosemide | 261 | 73 |
| Gabapentin | Gabapentin | 246 | 72 |
| Metoprolol Tartrate | Metoprolol Tartrate | 243 | 71 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 226 | 66 |
| Simvastatin | Simvastatin | 216 | 50 |
| Prednisone | Prednisone | 202 | 129 |
| Tramadol Hcl | Tramadol Hcl | 200 | 48 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 197 | 22 |
| Losartan Potassium | Losartan Potassium | 197 | 62 |
| Potassium Chloride | Potassium Chloride | 183 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 181 | 50 |
| Glimepiride | Glimepiride | 168 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 164 | 56 |
| Meloxicam | Meloxicam | 154 | 58 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 152 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 152 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 148 | 46 |
| Mirtazapine | Mirtazapine | 144 | 32 |
| Montelukast Sodium | Montelukast Sodium | 128 | 28 |
| Eliquis | Apixaban | 122 | 32 |
| Trazodone Hcl | Trazodone Hcl | 113 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 99 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 98 | 34 |
| Carvedilol | Carvedilol | 95 | 26 |
| Donepezil Hcl | Donepezil Hcl | 91 | 32 |
| Allopurinol | Allopurinol | 89 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 89 | 61 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 21 |
| Sildenafil Citrate | Sildenafil Citrate | 84 | 15 |
| Azithromycin | Azithromycin | 83 | 64 |
| Clonidine Hcl | Clonidine Hcl | 83 | 14 |
| Alendronate Sodium | Alendronate Sodium | 82 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 80 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 80 | 61 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 79 | 32 |
| Clonazepam | Clonazepam | 78 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 77 | 22 |
| Lovastatin | Lovastatin | 75 | 18 |
| Sertraline Hcl | Sertraline Hcl | 73 | 19 |
| Meclizine Hcl | Meclizine Hcl | 71 | 23 |
| Bupropion Hcl Sr | Bupropion Hcl | 68 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 66 | 16 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 66 | 15 |
| Diazepam | Diazepam | 65 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 64 | 16 |
| Ondansetron Odt | Ondansetron | 64 | 21 |
| Cephalexin | Cephalexin | 60 | 50 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 12 |
| Warfarin Sodium | Warfarin Sodium | 55 | 12 |
| Folic Acid | Folic Acid | 53 | 13 |
| Famotidine | Famotidine | 52 | 18 |
| Finasteride | Finasteride | 51 | 16 |
| Spironolactone | Spironolactone | 51 | 20 |
| Methylprednisolone | Methylprednisolone | 49 | 40 |
| Atenolol | Atenolol | 47 | 17 |
| Lorazepam | Lorazepam | 46 | 11 |
| Ozempic | Semaglutide | 46 | suppressed |
| Pregabalin | Pregabalin | 46 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | 19 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 45 | 30 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 44 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 44 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 33 |
| Januvia | Sitagliptin Phosphate | 43 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | 13 |
| Xarelto | Rivaroxaban | 43 | 12 |
| Glipizide | Glipizide | 42 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 42 | suppressed |
| Ezetimibe | Ezetimibe | 41 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 40 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 39 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 39 | 12 |
| Naproxen | Naproxen | 39 | suppressed |
| Ibuprofen | Ibuprofen | 37 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | suppressed |
| Nifedipine Er | Nifedipine | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | 13 |
| Nystatin | Nystatin | 33 | 16 |
| Benzonatate | Benzonatate | 32 | 24 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 30 | suppressed |
| Tradjenta | Linagliptin | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Jardiance | Empagliflozin | 29 | suppressed |
| Dexamethasone | Dexamethasone | 28 | 25 |
| Temazepam | Temazepam | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 22 |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 19 |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | 16 |
| Sotalol | Sotalol Hcl | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | 11 |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Brilinta | Ticagrelor | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Humalog | Insulin Lispro | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 14 |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Phenobarbital | Phenobarbital | 18 | suppressed |
| Ssd | Silver Sulfadiazine | 18 | 12 |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 14 |
| Armour Thyroid | Thyroid,pork | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 13 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 12 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Tivicay | Dolutegravir Sodium | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $504.79 · 24 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, BREZTRI, COMIRNATY, EVENITY, FARXIGA, FREESTYLE LIBRE 2, GVOKE HYPOPEN, JARDIANCE, KISUNLA, Korlym, MOUNJARO, NURTEC ODT, OPSUMIT, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, TRELEGY ELLIPTA, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error